BioWorld - Wednesday, May 6, 2026

Articles Tagged with ''Ono Pharmaceutical Co. Ltd.''

Neurology/psychiatric

Ono Pharmaceutical, Wuxi Apptec identify GBA/GLCT-1 dual modulators

Sep. 23, 2024
Ono Pharmaceutical Co. Ltd. and Wuxi Apptec Co. Ltd. have jointly developed new ceramide glucosyltransferase (glucosylceramide synthase; GLCT-1) and lysosomal acid glucosylceramidase (GBA; β-glucocerebrosidase; β-glucosidase) dual inhibitors reported to be useful for the treatment of mild cognitive impairment, among others.
Read More

Deciphera says o-yes to $2.4B Ono acquisition

April 30, 2024
By Lee Landenberger
In a $2.4 billion deal, Deciphera Pharmaceuticals Inc. is merging with Ono Pharmaceutical Co. Ltd. Ono is acquiring all of Deciphera’s outstanding stock shares for $25.60 each in cash. The merger helps Osaka, Japan-based Ono strengthen its oncology portfolio and its presence in the U.S.
Read More

Deciphera says o-yes to $2.4B Ono acquisition

April 29, 2024
By Lee Landenberger
In a $2.4 billion deal, Deciphera Pharmaceuticals Inc. is merging with Ono Pharmaceutical Co. Ltd. Ono is acquiring all of Deciphera’s outstanding stock shares for $25.60 each in cash. The merger helps Osaka, Japan-based Ono strengthen its oncology portfolio and its presence in the U.S.
Read More
Cancer

Ono Pharmaceutical divulges new ABHD6 inhibitors

April 25, 2024
Ono Pharmaceutical Co. Ltd. has synthesized monoacylglycerol lipase ABHD6 inhibitors reported to be useful for the treatment of cancer, pain, neurological, inflammatory, autoimmune and metabolic diseases.
Read More
Woman and 3D brain
Neurology/Psychiatric

Ono and Sibylla collaborate in neurological disorders

March 15, 2024
Ono Pharmaceutical Co. Ltd. has entered into a collaboration agreement with Sibylla Biotech SpA to generate novel drug candidates for neurological disorders. Under this collaboration, Sibylla will utilize its proprietary Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) protein degradation technology platform.
Read More